Effectiveness of micafungin in treatment of malignant hematological disorders complicated with pulmonary invasive fungal infection:an analysis of 15 cases
7Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, riskbased, antifungal strategy in neutropenic patients[ J ]. Br J Haematol,2000 ,110 :273 - 284.
8Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis : disease spectrum, treatment practices, and outcomes [ J ]. Medicine ,2000,79:250 - 260.
9Walsh TJ, Hiemenz JW, Seibel NL, et al. Arnphotericin B lipid complex for invasive fungal infections : analysis of safety and efficacy in 556 cases[J]. Clin Infect Dis, 1998,26:1383 -1396.
10Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate : systematic review of the literature [ J ]. Clin Infect Dis, 2001,32 : 358 - 366.
4Park JS,Kim DH,Choi CW,et al. Efficacy and safety of mi- cafungin as an empirical antifungal agent for febrile neutro- penic patients with hematological diseases[J]. Acta Haema- tol,2010,124(2) :92-97.
5Aikawa N, Kusachi S, Oda S, et al. Clinical effects of micafun- gin, a novel echinocandin antifungal agent, On systemic fun- gal infections in surgery, emergency, and intensive-care med- icine: evaluation using the AKOTT algorithm[J]. J Infect Chemother, 2009,15(4): 219-227.
6Hirata Y,Yokote T,Kobayashi K,etal Antifungal prophy laxis with micafungin in neutropenic patients with hematolog ical malignancies [J]. Leuk Lymphoma, 2010, 51 ( 5 ):853-859.
7Yoshizawa S, Gotoh M, Kitahara T, et al. Micafungin-induced hemolysis attack due to drug-dependent antibody persisting for more than 6 weeks[J]. Leuk Res,2010,34(2):e60-e61.
9AE Hershey,ID Kurzman,LJ Forrest,CA Bohling,M Stonerook,ME Placke.Inhalation chemotherapy for macroscopic primary or metastatic lung tumors:proof of principle using dogs with spontaneously occurring tumors as a model[].Clinical Cancer Research.2010
10JS Patton,PR Byron.Inhaling medicines:delivering drugs to the body through the lungs[].Nature Reviews Drug Discovery.2011
